Company Overview and News
TRADING of the shares in Choo Bee Metal Industries Bhd (fundamental: 2.05/3, valuation: 3/3) triggered our momentum algorithm yesterday for the first time this year. The counter saw 774,300 shares traded compared to its 200-day average of 129,530.5.
KUALA LUMPUR (Aug 15): Shares in Choo Bee Metal Industries Bhd jumped 6.38% this morning after its second quarter net profit rose 62.51% on-year to RM10.25 million from RM6.31 million, on higher selling prices and better margins.
5797 BSMAF 1818
KUALA LUMPUR (Aug 15): The FBM KLCI held on to its marginal gains at mid-morning today, despite the retreat at most regional markets, propped up by Petronas-linked stocks.
APEXF 5161 7090 0090 7192 8621 5681 JCYBF BATS 4162 7034 6033 5101 PNADF 3301 5797 6556 5819 PNAGF
KUALA LUMPUR (Aug 14): Choo Bee Metal Industries Bhd's second quarter net profit rose 62.51% on-year to RM10.25 million from RM6.31 million, on higher selling prices and better margins.
5797 BSMAF 1818
KUALA LUMPUR (Aug 13): Malaysia's steel sector is likely to experience further headwinds, as global demand is likely to be further hit by shaky demand from China's waning construction sector, in addition to risks from trade war tariffs, said MIDF Amanah Investment Bank Bhd Research.
5797 5665 6556 5094 5087 9199
Construction sector Maintain neutral: Post-14th general election, the new Pakatan Harapan government embarked on a review of all megaprojects, as promised in its election manifesto. The Kuala Lumpur-Singapore high-speed rail (RM60 billion to RM70 billion) and mass rapid transit Line 3 (MRT3) (RM40 billion) were shelved shortly thereafter. Although there were reports regarding the revival of these projects, we reckon that chances are slim in the near term.
9261 5843 3204 5797 5072 7014 9679 7078 5056
The possible announcement of the full Cabinet line-up could be among the highlights this week, even as businesses continue to cash in on the World Cup 2018 fever and the zero-rated Goods and Services Tax (GST) “tax holiday”. There was no Cabinet meeting last Wednesday (June 13) with Prime Minister Tun Dr Mahathir Mohamad just returning from a work trip in Japan (June 11 and 12) and Hari Raya Puasa festivities on June 15 and 16.
8591 5139 9571 5797 1996 0900 5263 5098 0065 5156
IPOH, June 8 — Perak Mentri Besar Ahmad Faizal Azumu denied his predecessor Datuk Seri Zambry Abd Kadir refused to move out from the former’s official residence.
KUALA LUMPUR: JF Apex Research expects ViTrox Corp Bhd , Frontken Corp Bhd , Ireka Corp Bhd , Choo Bee Metal Industries Bhd and Pavilion Real Estate Investment Trust (Reit) to generate trading interest following their latest news.
Ready for shipping: A file picture showing steel coils produced at a steel mill in Indiana being prepared for shipping. Local steel stocks have fallen 18.3 after the US announced proposed tariffs on steel and aluminium imports. — AFP
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...